NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
39 trialsNCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT00437372 2025-05-02
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Thomas Jefferson University
Phase 1 Completed
NCT00330564 2024-06-27
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04033991 2023-04-06
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Pfizer
Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT02239952 2020-10-08
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Amsterdam UMC, location VUmc
Phase NA Unknown
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT01391130 2019-07-23
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Phase 2 Terminated
NCT02386111 2018-07-26
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
Phase 1 Terminated
NCT00463060 2018-07-18
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01108445 2018-01-16
ASPEN
Duke University
Phase 2 Completed
NCT01784978 2017-10-02
SUNRISES
Associació per a la Recerca Oncologica, Spain
Phase 2 Terminated
NCT00400114 2017-05-08
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00617253 2017-03-01
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Novo Nordisk A/S
Phase 2 Completed
NCT01054911 2016-09-22
Evaluation of Patients With Bulky GIST Using Sunitinib
University of Alabama at Birmingham
Phase NA Terminated
NCT00705874 2016-07-21
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
Phase 1 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01215565 2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT00980213 2014-02-06
Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
Tampere University Hospital
Completed
NCT00402415 2013-12-18
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
Yale University
Phase 1 Terminated
NCT00443534 2013-05-24
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Pfizer
Phase NA Completed
NCT01850147 2013-05-09
Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
ChineseAMS
Phase 2 Unknown
NCT00510640 2013-02-28
THYSU
University Hospital, Bordeaux
Phase 2 Completed
NCT00434109 2012-09-14
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01548170 2012-03-08
To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Phase 1 Completed
NCT00673504 2011-12-01
First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00528619 2011-04-08
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00732992 2011-03-17
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Pfizer
Phase 1 Completed
NCT00618124 2010-05-03
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
Pfizer
Phase 1 Completed
NCT00615446 2010-04-30
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00511849 2010-02-17
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed